Table 3.

Effect of time since last use and duration of hormone replacement therapy on risk of hip fracture

AnyWithout progestinWith progestin
Use of hormone replacement therapyNo of cases/ controlsOdds ratio*No of cases/ controlsOdds ratio*No of cases/ controlsOdds ratio*
(95% Cl)(95% Cl)(95% Cl)
Never used956/20731.00 (reference)956/20731.00(reference)956/20731.00(reference)
Last use 12 months:
Any use47/2600.38(0.26 to 0.56)21/700.61(0.35 to 1.04)28/1980.28(0.17 to 0.47)
Total use >5 years14/970.28(0.16 to 0.51)8/360.35(0.15 to 0.82)9/660.24(0.11 to 0.52)
Per year of use0.92(0.88 to 0.96)0.93(0.88 to 0.98)0.88(0.82 to 0.95)
Last use 13-60 months:
Any use11/450.52(0.26 to 1.04)9/230.82(0.37 to 1.84)7/310.42(0.17 to 1.04)
Total use >5 years3/180.27 (0.08 to 0.94)3/60.65(0.14 to 3.05)1/120.10(0.01 to 0.87)
Per year of use0.91(0.82 to 1.00)0.97(0.86 to 1.09)0.78(0.63 to 0.97)
Last use >60 months:
Any use46/1250.75(0.52 to 1.07)38/1150.65(0.44 to 0.96)17/381.00(0.55 to 1.82)
Total use >5 years15/281.07(0.57 to 2.03)12/221.06(0.52 to 2.19)3/80.74(0.19 to 2.93)
Per year of use0.98(0.92 to 1.04)0.98(0.91 to 1.05)0.96(0.83 to 1.12)
  • *Adjusted for age (50 to 54, 55 to 59, 60 to 64, 65 to 69, 70 to 74, 75 to 81 years) and the indication of hormone replacement therapy to prevent osteoporosis (yes/no).